Fig. 1 | Cell Death & Differentiation

Fig. 1

From: A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness

Fig. 1

miR-30a-5p and miR-30a-3p expression in breast cancers of the TCGA series (ac) and of the in-house series (d–f). TCGA series: a the expression levels of miR-30a-5p and miR-30a-3p (expressed as LOG2 RPM) are lower in breast tumors (T) compared to matched normal breast tissues (N; 12 cases). b, c miR-30a-5p and miR-30a-3p levels are lower in the 82 BCs carrying TP53 mutations (missense, nonsense, frameshift; TP53 mut) compared to the 163 TP53 wild-type tumors (TP53 WT) (b) and in TNBC (27 cases) compared to hormone receptor-positive tumors (HR, 204 cases) (c). The p values were calculated by Mann–Whitney rank sum test; *p < 0.05, **p < 0.01. In-house series: d low levels of either miRNA strand are associated with lymph node positivity. Data are reported as LOG2 of miRNA relative levels; p values were calculated by two-tailed t-test; *p < 0.05, **p < 0.01. e, f Kaplan–Meier analysis showing overall survival in the TNBC patients classified according to miR-30a-5p (e) and miR-30a-3p (f) median levels. Survival curves are truncated at 84 months. In (ad) lines within the boxes mark the median, boundaries represent the 25th and the 75th percentiles and whiskers below and above the boxes indicate the 5th and 95th percentiles

Back to article page